Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

InnoCare Doses First Patient in Trial of Protein Degrader for Myeloma and Lymphoma

publication date: Apr 6, 2023

Beijing InnoCare Pharma has dosed the first subject in a China Phase I trial of its novel targeted protein degrader ICP-490 to treat multiple myeloma and non-Hodgkin's lymphoma. ICP-490, a CRBM Modulator, was developed by InnoCare’s molecular glue platform and is expected to cause anti-tumor effects in various multiple myeloma and diffuse large B cell lymphoma cancers. Because it enhances ADCC activity, ICP-490 is also expected to be a good combination therapy with InnoCare’s other candidates, especially the CD19 inhibitor tafasitamab. More details....

Stock Symbols: (HK: 09969; SHA: 688428)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital